These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 28710865

  • 1. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Mar; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 3. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
    Bulent Akinci M, Algin E, Inal A, Odabas H, Berk V, Coskun U, Uyeturk U, Isikdogan A, Aksoy S, Civelek B, Sevinc A, Buyukberber S.
    J BUON; 2013 Mar; 18(2):314-20. PubMed ID: 23818340
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S, Kwiatkowski F, Abrial C, Wang-Lopez Q, de Boissieu P, Garbar C, Bensussan A, Curé H.
    Oncology; 2015 Mar; 88(5):261-72. PubMed ID: 25573741
    [Abstract] [Full Text] [Related]

  • 5. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.
    Diagn Pathol; 2017 Feb 21; 12(1):20. PubMed ID: 28222768
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M.
    Breast J; 2018 May 21; 24(3):269-277. PubMed ID: 28929593
    [Abstract] [Full Text] [Related]

  • 9. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan 21; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 10. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.
    J Clin Oncol; 2012 May 20; 30(15):1796-804. PubMed ID: 22508812
    [Abstract] [Full Text] [Related]

  • 11. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M, Ma F, Wang J, Li Q, Zhang P, Yuan P, Luo Y, Cai R, Fan Y, Chen S, Li Q, Xu B.
    Chin J Cancer; 2018 Jan 31; 37(1):4. PubMed ID: 29382381
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.
    Wang H, Zhang N, Sun Q, Zhao Z, Pang H, Huang X, Zhang R, Kang W, Shan M.
    J Cancer Res Clin Oncol; 2024 Jun 05; 150(6):291. PubMed ID: 38836955
    [Abstract] [Full Text] [Related]

  • 13. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T.
    J BUON; 2015 Jun 05; 20(1):45-9. PubMed ID: 25778295
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
    Kern P, Kalisch A, von Minckwitz G, Pütter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R.
    J Chemother; 2016 Jun 05; 28(3):210-7. PubMed ID: 26239282
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT.
    Ann Oncol; 2014 Feb 05; 25(2):384-91. PubMed ID: 24351399
    [Abstract] [Full Text] [Related]

  • 16. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
    Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F.
    Ann Oncol; 2014 Aug 05; 25(8):1570-7. PubMed ID: 24827135
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience.
    Singareeka Raghavendra A, Liu D, Shen Y, Barcenas CH, Ueno NT, Giordano S, Tripathy D, Sri Karuturi M.
    Breast Cancer Res Treat; 2024 Aug 05; 207(1):81-90. PubMed ID: 38916821
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.